Chiesi Farmaceutici

Chiesi Farmaceutici S.p.A. is an Italian family controlled global pharmaceutical company based in Parma, Emilia-Romagna. Chiesi has 30 affiliates in the world, nearly 6,389 total employees and provides medicines to patients in 90 nations. Chiesi currently has revenues of 2.229 billion euros. According to 2020 official data from the European Patent Office (EPO), Chiesi Group, with 38 patents filed, is confirmed the first Italian Pharmaceutical Company and fourth among Italian Companies across all sectors for filing the highest number of patents.

Trade Name	Drug Name	Approved	Patent Expires	Indication
Bethkis	Tobramycin	2012-10-12	2024-2030	Cystic fibrosis , Respiratory tract infections , Bacterial eye infections , Bacterial infections , Central nervous system infections , Infectious bone diseases , Infectious skin diseases , Intraabdominal infections , Pseudomonas infections , Staphylococcal infections , Urinary tract infections
Bronchitol	Mannitol	2020-10-30		Cystic fibrosis , Anuria , Brain edema , Ocular hypertension , Oliguria
Cardene	Nicardipine	1988-12-21	2027	Hypertension , Stable angina , Variant angina pectoris
Cleviprex	Clevidipine	2008-08-01	2031	Hypertension
Curosurf	Poractant alfa	1999-11-18		Newborn respiratory distress syndrome
Envarsus	Tacrolimus	2014-07-18	2024-2028	Atopic dermatitis, Graft rejection, Kidney transplantation, Liver transplantation, Graft vs host disease
Ferriprox	Deferiprone	2011-10-14	2029-2038	Beta-thalassemia, Iron overload
Kengreal	Cangrelor	2015-06-22	2029-2035	Acute coronary syndrome, Vascular surgical procedures
Kengrexal	Cangrelor	2015-03-23	2029-2035	Acute coronary syndrome, Vascular surgical procedures
Lamzede	Velmanase alfa	2023-02-16		Alpha-mannosidosis